FOIL starts NYSE trading at $22; VOGX also debuts, no retail IPO window verified
FOIL reaches its expected NYSE debut at a $22 IPO price while VOGX also starts trading; neither deal has a publicly verified mainstream-broker IPO allocation window.
Wednesday, August 12 is a normal NYSE and Nasdaq trading day. The practical takeaway: FOIL has moved from price discovery to its expected first trading session, while VOGX is also debuting—but neither has a verified mainstream-broker IPO allocation window. 1
Today's spotlight: Londian Wason New Energy Tech (FOIL)
Status: Priced at $22 per ADS, the top of its prior $20-$22 range; NYSE trading is expected to begin today. The offering is expected to close Thursday, August 13, subject to customary conditions. 2
Business in one sentence: Londian Wason makes electrolytic copper foil used in lithium-ion batteries and electronic-circuit applications. 3
Why retail investors care: This is a direct bet on a battery-supply-chain manufacturer rather than a broad clean-energy theme. The company says it supplied about 111,985 metric tons of lithium-ion battery copper foil in 2025 and held a 7.6% global share by sales volume, based on Frost & Sullivan data cited in its IPO materials. Its named customers include CATL, BYD, LG Energy Solution, Samsung SDI and Panasonic. 4
The number to watch: The deal grew from roughly 3.6 million ADSs in the initial calendar terms to about 4.3 million ADSs, producing approximately $94.3 million in gross proceeds and about $87 million in expected net proceeds. The company says it plans to use the money for production expansion, facility upgrades, research and development, manufacturing efficiency and product expansion. 2
Risk to monitor: FOIL is exposed to battery demand, copper-foil pricing and execution on capacity expansion. The IPO also creates dilution: the offered ADSs are newly issued, and underwriters have a 30-day option for up to 642,857 more ADSs. 2
Minimum buy-in and broker access: $22 is the IPO price, not a verified retail minimum. No public allocation notice through Robinhood, Fidelity, Schwab, E*TRADE or Webull was verified. If FOIL appears in a brokerage app today, that is ordinary secondary-market trading—not proof that the $22 IPO was available to that account.
Actionable now
No US IPO allocation met all four checks for this edition: public offer terms, a live deadline, a minimum buy-in and a verified mainstream-broker path. VOGX has priced, but its public release names the underwriter and expected closing date—not a retail order channel. 56
| Ticker | Price range | Minimum buy-in | Deadline | Verified brokers | Status |
|---|---|---|---|---|---|
| None verified | — | Not disclosed | No public allocation window found | None publicly verified | Watch only |
Market pulse
- VOGX priced at the top of its range. Vogenx sold 6.25 million shares at $13, expects about $81.3 million in gross proceeds and is expected to start Nasdaq trading today. It is a clinical-stage biotech, so the value still depends on development and regulatory milestones rather than current product sales. 5
- Selective biotech demand is still showing up. BioSpace reported that BlossomHill increased its offering to nearly 9.4 million shares and expects $150 million, versus an initial target of about $129.1 million. Latigo raised about $345.6 million, above its earlier $285.2 million target. Those are deal-size and demand signals for selected issuers, not proof that every new listing will trade higher. 7
- Defense technology remains a live IPO theme. Lyntris is marketing 24 million shares at $19-$22, with a reported backlog of $923.9 million as of June 30. Reuters also reported a six-month net loss of $13 million on $241 million of revenue. The combination is simple to read: a large backlog, but a company that is not yet profitable. 8
HK desk
No Hong Kong public subscription is verified as open today or closing by Friday, August 14. The accessible ET Net IPO route returned an unavailable-page response, while HKEX's public page available in the current search is a newly listed-securities page, not a live subscription table. That leaves this desk at no verified action, rather than turning a listing notice or an old offer into a current application opportunity. 9
On the radar: August 12-26
| Deal | Pricing date | Expected listing | Terms | Why watch |
|---|---|---|---|---|
| Lyntris (LYNX) | Not disclosed | Aug. 19, NYSE | 24M shares at $19-$22; about $492M at the midpoint | Defense sensors and software, a large backlog, and an acquisition-led growth story; the reported loss makes execution and profitability the check. 68 |
The reviewed public calendars did not disclose a separate LYNX pricing date or another dated traditional US company IPO with complete terms inside the next two weeks. The radar stays short rather than padding it with undated filings, funds or warrant events.
Market information only, not investment advice. IPO terms, dates and access can change before a final prospectus, pricing or listing.
References
- 1Stock market holidays 2026
fidelity.com
- 2Londian Wason IPO pricing release
prnewswire.com
- 3Londian Wason IPO pricing release
stocktitan.net
- 4Londian Wason IPO profile
renaissancecapital.com
- 5Vogenx IPO pricing release
biospace.com
- 6Renaissance Capital IPO calendar
renaissancecapital.com
- 7BlossomHill and Latigo IPOs
biospace.com
- 8Lyntris IPO coverage
reuters.com
- 9HKEX newly listed securities
hkex.com.hk
This story was produced automatically by a channel. One sentence is all it takes for Neodrop to keep producing for you.